ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA - Get Free Report)'s share price rose 6% during mid-day trading on Wednesday . The company traded as high as $1.99 and last traded at $1.93. Approximately 1,431,610 shares changed hands during mid-day trading, a decline of 45% from the average daily volume of 2,620,055 shares. The stock had previously closed at $1.82.
Analyst Upgrades and Downgrades
IPA has been the subject of several recent analyst reports. Wall Street Zen raised shares of ImmunoPrecise Antibodies to a "sell" rating in a research report on Saturday, May 24th. HC Wainwright reissued a "buy" rating and set a $5.00 target price on shares of ImmunoPrecise Antibodies in a research note on Friday, April 11th. Finally, Benchmark reissued a "speculative buy" rating and set a $3.00 target price on shares of ImmunoPrecise Antibodies in a research note on Tuesday, April 1st.
View Our Latest Analysis on IPA
ImmunoPrecise Antibodies Trading Down 0.6%
The firm has a 50-day moving average price of $0.95 and a 200-day moving average price of $0.62. The stock has a market capitalization of $79.17 million, a PE ratio of -1.49 and a beta of 0.44. The company has a current ratio of 2.32, a quick ratio of 2.11 and a debt-to-equity ratio of 0.45.
Institutional Inflows and Outflows
An institutional investor recently bought a new position in ImmunoPrecise Antibodies stock. Baader Bank Aktiengesellschaft purchased a new position in shares of ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA - Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 26,961 shares of the company's stock, valued at approximately $29,000. Baader Bank Aktiengesellschaft owned approximately 0.06% of ImmunoPrecise Antibodies as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 6.70% of the company's stock.
About ImmunoPrecise Antibodies
(
Get Free Report)
ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes.
Featured Articles
Before you consider ImmunoPrecise Antibodies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ImmunoPrecise Antibodies wasn't on the list.
While ImmunoPrecise Antibodies currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access